Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Acad Child Adolesc Psychiatry ; 51(2): 136-46, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22265360

ABSTRACT

OBJECTIVE: Children with Pervasive Developmental Disorders (PDDs) have social interaction deficits, delayed communication, and repetitive behaviors as well as impairments in adaptive functioning. Many children actually show a decline in adaptive skills compared with age mates over time. METHOD: This 24-week, three-site, controlled clinical trial randomized 124 children (4 through 13 years of age) with PDDs and serious behavioral problems to medication alone (MED; n = 49; risperidone 0.5 to 3.5 mg/day; if ineffective, switch to aripiprazole was permitted) or a combination of medication plus parent training (PT) (COMB; n = 75). Parents of children in COMB received an average of 11.4 PT sessions. Standard scores and Age-Equivalent scores on Vineland Adaptive Behavior Scales were the outcome measures of primary interest. RESULTS: Seventeen subjects did not have a post-randomization Vineland assessment. Thus, we used a mixed model with outcome conditioned on the baseline Vineland scores. Both groups showed improvement over the 24-week trial on all Vineland domains. Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively). On Age Equivalent scores, Socialization and Communication domains showed greater improvement in COMB versus MED (p = .03 and 0.05, and effect sizes = 0.33 and 0.14, respectively). Using logistic regression, children in the COMB group were twice as likely to make at least 6 months' gain (equal to the passage of time) in the Vineland Communication Age Equivalent score compared with MED (p = .02). After controlling for IQ, this difference was no longer significant. CONCLUSION: Reduction of serious maladaptive behavior promotes improvement in adaptive behavior. Medication plus PT shows modest additional benefit over medication alone. Clinical trial registration information-RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders; http://www.clinicaltrials.gov; NCT00080145.


Subject(s)
Adaptation, Psychological/drug effects , Antipsychotic Agents/therapeutic use , Child Behavior Disorders/therapy , Child Development Disorders, Pervasive/therapy , Education , Risperidone/therapeutic use , Adolescent , Antipsychotic Agents/adverse effects , Asperger Syndrome/diagnosis , Asperger Syndrome/psychology , Asperger Syndrome/therapy , Autistic Disorder/diagnosis , Autistic Disorder/psychology , Autistic Disorder/therapy , Checklist , Child , Child Behavior Disorders/diagnosis , Child Behavior Disorders/psychology , Child Development Disorders, Pervasive/diagnosis , Child Development Disorders, Pervasive/psychology , Child, Preschool , Combined Modality Therapy , Communication , Cooperative Behavior , Dose-Response Relationship, Drug , Female , Humans , Male , Risperidone/adverse effects , Socialization
2.
J Am Acad Child Adolesc Psychiatry ; 48(12): 1143-54, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19858761

ABSTRACT

OBJECTIVE: Many children with pervasive developmental disorders (PDDs) have serious, functionally impairing behavioral problems. We tested whether combined treatment (COMB) with risperidone and parent training (PT) in behavior management is superior to medication alone (MED) in improving severe behavioral problems in children with PDDs. METHOD: This 24-week, three-site, randomized, parallel-groups clinical trial enrolled 124 children, aged 4 through 13 years, with PDDs, accompanied by frequent tantrums, self-injury, and aggression. The children were randomized 3:2 to COMB (n = 75) or MED (n = 49). The participants received risperidone monotherapy from 0.5 to 3.5 mg/day (with switch to aripiprazole if risperidone was ineffective). Parents in the COMB group (n = 75; 60.5%) received a mean of 10.9 PT sessions. The primary measure of compliance was the Home Situations Questionnaire (HSQ) score. RESULTS: Primary: intent-to-treat random effects regression showed that COMB was superior to MED on HSQ (p = .006) [effect size at week 24 (d) = 0.34]. The HSQ score declined from 4.31 (± 1.67) to 1.23 (± 1.36) for COMB compared with 4.16 (± 1.47) to 1.68 (± 1.36) for MED. Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, COMB showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04). Final risperidone mean dose for MED was 2.26 mg/day (0.071 mg/kg), compared with 1.98 mg/day for COMB (0.066 mg/kg) (p = .04). CONCLUSIONS: Medication plus PT resulted in greater reduction of serious maladaptive behavior than MED in children with PDDs, with a lower risperidone dose.


Subject(s)
Antipsychotic Agents/therapeutic use , Child Behavior Disorders/therapy , Child Development Disorders, Pervasive/therapy , Education , Risperidone/therapeutic use , Adolescent , Antipsychotic Agents/adverse effects , Behavior Therapy , Child , Child Behavior Disorders/diagnosis , Child Behavior Disorders/psychology , Child Development Disorders, Pervasive/diagnosis , Child Development Disorders, Pervasive/psychology , Child, Preschool , Combined Modality Therapy , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Personality Assessment/statistics & numerical data , Psychometrics , Risperidone/adverse effects
3.
J Child Adolesc Psychopharmacol ; 19(3): 265-74, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19519261

ABSTRACT

OBJECTIVE: The aim of this study was to determine the effectiveness and tolerability of aripiprazole for irritability in pervasive developmental disorder not otherwise specified (PDD-NOS) and Asperger's disorder. METHOD: This is a 14-week, prospective, open-label investigation of aripiprazole in 25 children and adolescents diagnosed with PDD-NOS or Asperger's disorder. Primary outcome measures included the Clinical Global Impressions-Improvement (CGI-I) scale and the Irritability subscale of the Aberrant Behavior Checklist (ABC-I). RESULTS: Twenty-five subjects, ages 5-17 years (mean 8.6 years) received a mean final aripiprazole dosage of 7.8 mg/day (range 2.5-15 mg/day). Full-scale intelligence quotient (IQ) scores ranged from 48 to 122 (mean 84). Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final CGI-I of 1 or 2 (very much or much improved) and a 25% or greater improvement on the ABC-I. The final mean CGI-I was 1.6 (p

Subject(s)
Antipsychotic Agents/therapeutic use , Asperger Syndrome/drug therapy , Child Development Disorders, Pervasive/drug therapy , Piperazines/therapeutic use , Quinolones/therapeutic use , Adolescent , Antipsychotic Agents/adverse effects , Aripiprazole , Asperger Syndrome/physiopathology , Body Mass Index , Child , Child Development Disorders, Pervasive/physiopathology , Child, Preschool , Female , Humans , Irritable Mood/drug effects , Male , Pilot Projects , Piperazines/adverse effects , Prolactin/drug effects , Prolactin/metabolism , Prospective Studies , Psychiatric Status Rating Scales , Psychometrics , Quinolones/adverse effects , Severity of Illness Index
4.
J Am Acad Child Adolesc Psychiatry ; 42(12): 1443-50, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14627879

ABSTRACT

OBJECTIVE: A consumer-oriented efficacy assessment in clinical trials should measure changes in chief complaint and consumer request (symptoms of most concern to patient/caregiver), which may be diluted in change scores of multisymptom scales. METHOD: In the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network 8-week double-blind trial of risperidone versus placebo, the chief concerns of parents were collected at 0, 4, and 8 weeks (endpoint), in addition to standardized primary measures. Blinded clinical judges rated change from baseline to 4 and 8 weeks on a 9-point scale (1 = normalized, 5 = unchanged, 9 = disastrous); 94 participants had usable data. RESULTS: The most common symptoms identified by parents were tantrums, aggression, and hyperactivity. Interrater reliability was excellent. Mean ratings at endpoint were 2.8 +/- 1.2 on risperidone and 4.5 +/- 1.3 on placebo (p <.001). Ratings were collinear with Clinical Global Impression-Improvement and Aberrant Behavior Checklist Irritability subscale (primary dimensional measure). Effect size d was 1.4, compared to 1.2 on the Aberrant Behavior Checklist Irritability subscale. Effect sizes varied twofold by symptom category, largest for self-injury (2.11) and tantrums (1.95). CONCLUSIONS: Risperidone was superior to placebo in reducing symptoms of most concern to parents of autistic children with irritable behavior. Rating individualized participant-chosen target symptoms seems a reliable, sensitive, efficient, and consumer-friendly way to assess treatment effect and might have clinical application.


Subject(s)
Autistic Disorder/drug therapy , Clinical Trials as Topic , Dopamine Antagonists/therapeutic use , Parent-Child Relations , Risperidone/therapeutic use , Adolescent , Adult , Affect , Aggression , Autistic Disorder/psychology , Child , Dopamine Antagonists/pharmacology , Double-Blind Method , Endpoint Determination , Female , Humans , Male , Observer Variation , Placebos , Research Design , Risperidone/pharmacology , Severity of Illness Index , Stereotyped Behavior , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...